Abstract
Background/purpose
Optimal care for elderly patients with glioblastoma (GBM) remains in question due to their exclusion from and underrepresentation in many clinical trials (including EORTC 22,981) as well as their historically poor overall survival.
Methods
A retrospective chart review was conducted at a single high-volume cancer center for newly diagnosed elderly (65 years old or older) GBM patients diagnosed from 2011 through 2017.
Results
A total of 158 newly diagnosed GBM patients aged 65 years and older were identified. One hundred forty-four patients (91.1%) received radiotherapy (RT) and 130 patients (90.3%) received concurrent temozolomide with RT. Sixty-one patients (38.6%) completed concurrent chemoradiation and 6 cycles of adjuvant temozolomide. 23% of patients discontinued temozolomide during concurrent or adjuvant treatment due to side effects or complications of chemotherapy.
With a median follow-up time of 35.0 months, median overall survival (OS) time for the full cohort was 18.6 months, with estimated OS rates of 74.8%, 35.9%, and 9.5% at 1, 2, and 5 years, respectively. On multivariable analysis, higher KPS (p = 0.002, HR 0.46; 95% CI 0.63–0.82), completing planned RT course (p = 0.01, HR 0.29; 95% CI 0.11–0.75), and completing 6 cycles of adjuvant temozolomide (p = 0.01, HR 2.62; 95% CI 1.67–4.12) were independently associated with improved OS.
Conclusions
Our cohort of elderly GBM patients was predominantly treated with standard of care therapy based on EORTC 22,981. Despite their age, these patients generally tolerated treatment well and had favorable outcomes compared to those reported for patients treated on EORTC 22,981. Based on these findings, using advanced age as the basis for treatment de-escalation or as an exclusionary criterion in clinical trials should be discouraged.
Similar content being viewed by others
References
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. https://doi.org/10.1056/NEJMoa043330
Laperriere N, Weller M, Stupp R, Perry JR, Brandes AA, Wick W, van den Bent MJ (2013) Optimal management of elderly patients with glioblastoma. Cancer Treat Rev 39:350–357. https://doi.org/10.1016/j.ctrv.2012.05.008
Paszat L, Laperriere N, Groome P, Schulze K, Mackillop W, Holowaty E (2001) A population-based study of glioblastoma multiforme. Int J Radiat Oncol Biol Phys 51:100–107
Perry JR, Laperriere N, O'Callaghan CJ, Brandes AA, Menten J, Phillips C, Fay M, Nishikawa R, Cairncross JG, Roa W, Osoba D, Rossiter JP, Sahgal A, Hirte H, Laigle-Donadey F, Franceschi E, Chinot O, Golfinopoulos V, Fariselli L, Wick A, Feuvret L, Back M, Tills M, Winch C, Baumert BG, Wick W, Ding K, Mason WP, Trial I (2017) Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med 376:1027–1037. https://doi.org/10.1056/NEJMoa1611977
Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS (2018) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011–2015. Neuro-oncology 20:iv1–iv86. https://doi.org/10.1093/neuonc/noy131
Roa W, Brasher PM, Bauman G, Anthes M, Bruera E, Chan A, Fisher B, Fulton D, Gulavita S, Hao C, Husain S, Murtha A, Petruk K, Stewart D, Tai P, Urtasun R, Cairncross JG, Forsyth P (2004) Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 22:1583–1588. https://doi.org/10.1200/JCO.2004.06.082
Malmstrom A, Gronberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi ME, Rosell J, Henriksson R, Nordic Clinical Brain Tumour Study G (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 13:916–926. https://doi.org/10.1016/S1470-2045(12)70265-6
Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Combs SE, Vesper J, Braun C, Meixensberger J, Ketter R, Mayer-Steinacker R, Reifenberger G, Weller M, Society NOASGoN-oWGoGC (2012) Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 13:707–715. https://doi.org/10.1016/S1470-2045(12)70164-X
Palmer JD, Bhamidipati D, Mehta M, Williams NL, Dicker AP, Werner-Wasik M, Shi W (2018) Treatment recommendations for elderly patients with newly diagnosed glioblastoma lack worldwide consensus. J Neurooncol 140:421–426. https://doi.org/10.1007/s11060-018-2969-3
Seppälä M, Raj R, Korja M, Pitkäniemi J, Seppä K, Malila N, Luostarinen T, Mäenpää H (2018) Glioblastoma survival is improving despite increasing incidence rates: a nationwide study between 2000 and 2013 in Finland. Neuro-oncology 21:370–379. https://doi.org/10.1093/neuonc/noy164
Huang B, Liu M, Villano JL, Pittman T, Garcia CR, Dolecek TA, Dressler EV (2018) Patterns and disparities of care in glioblastoma. Neuro-oncol Pract 6:37–46. https://doi.org/10.1093/nop/npy014
Wick A, Kessler T, Elia AEH, Winkler F, Batchelor TT, Platten M, Wick W (2018) Glioblastoma in elderly patients: solid conclusions built on shifting sand? Neuro-oncology 20:174–183. https://doi.org/10.1093/neuonc/nox133
Keime-Guibert F, Chinot O, Taillandier L, Cartalat-Carel S, Frenay M, Kantor G, Guillamo JS, Jadaud E, Colin P, Bondiau PY, Menei P, Loiseau H, Bernier V, Honnorat J, Barrie M, Mokhtari K, Mazeron JJ, Bissery A, Delattre JY (2007) Radiotherapy for glioblastoma in the elderly. N Engl J Med 356:1527–1535. https://doi.org/10.1056/NEJMoa065901
Heiland DH, Haaker G, Watzlawick R, Delev D, Masalha W, Franco P, Machein M, Staszewski O, Oelhke O, Nicolay NH, Schnell O (2018) One decade of glioblastoma multiforme surgery in 342 elderly patients: what have we learned? J Neurooncol 140:385–391. https://doi.org/10.1007/s11060-018-2964-8
Jackson WC, Tsien CI, Junck L, Leung D, Hervey-Jumper S, Orringer D, Heth J, Wahl DR, Spratt DE, Cao Y, Lawrence TS, Kim MM (2018) Standard dose and dose-escalated radiation therapy are associated with favorable survival in select elderly patients with newly diagnosed glioblastoma. J Neurooncol 138:155–162. https://doi.org/10.1007/s11060-018-2782-z
Bingham B, Patel CG, Shinohara ET, Attia A (2018) Utilization of hypofractionated radiotherapy in treatment of glioblastoma multiforme in elderly patients not receiving adjuvant chemoradiotherapy: a National Cancer Database Analysis. J Neurooncol 136:385–394. https://doi.org/10.1007/s11060-017-2665-8
Lu VM, Kerezoudis P, Brown DA, Burns TC, Quinones-Hinojosa A, Chaichana KL (2019) Hypofractionated versus standard radiation therapy in combination with temozolomide for glioblastoma in the elderly: a meta-analysis. J Neurooncol. https://doi.org/10.1007/s11060-019-03155-6
Mak KS, Agarwal A, Qureshi MM, Truong MT (2017) Hypofractionated short-course radiotherapy in elderly patients with glioblastoma multiforme: an analysis of the National Cancer Database. Cancer Med 6:1192–1200. https://doi.org/10.1002/cam4.1070
Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, Otten P, Van Melle G, de Tribolet N, Stupp R (2004) Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 10:1871–1874
Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003. https://doi.org/10.1056/NEJMoa043331
Mansouri A, Hachem LD, Mansouri S, Nassiri F, Laperriere NJ, Xia D, Lindeman NI, Wen PY, Chakravarti A, Mehta MP, Hegi ME, Stupp R, Aldape KD, Zadeh G (2018) MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges. Neuro-oncology 21:167–178. https://doi.org/10.1093/neuonc/noy132
Lassman A, Dimino C, Mansukhani M, Murty V, Ansell PJ, Bain E, Holen KD, Roberts-Rapp LA, Lee J, Curran W, Mehta MP, Canoll P (2017) ACTR-68. Concordance of EGFR and MGMT analyses between local and central laboratories: implications for clinical trial design and precision medicine for depatuxizumab-mafodotin (ABT-414) in glioblastoma (GBM). Neuro-oncology 19:vi15. https://doi.org/10.1093/neuonc/nox168.055
Kessler T, Sahm F, Sadik A, Stichel D, Hertenstein A, Reifenberger G, Zacher A, Sabel M, Tabatabai G, Steinbach J, Sure U, Krex D, Grosu A-L, Bewerunge-Hudler M, Jones D, Pfister SM, Weller M, Opitz C, Bendszus M, von Deimling A, Platten M, Wick W (2018) Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation. Neuro-oncology 20:367–379. https://doi.org/10.1093/neuonc/nox160
Nguyen HN, Lie A, Li T, Chowdhury R, Liu F, Ozer B, Wei B, Green RM, Ellingson BM, Wang HJ, Elashoff R, Liau LM, Yong WH, Nghiemphu PL, Cloughesy T, Lai A (2017) Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy. Neuro-oncology 19:394–404. https://doi.org/10.1093/neuonc/now189
Wiestler B, Claus R, Hartlieb SA, Schliesser MG, Weiss EK, Hielscher T, Platten M, Dittmann LM, Meisner C, Felsberg J, Happold C, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Grimm C, Weichenhan D, Tews B, Reifenberger G, Capper D, Muller W, Plass C, Weller M, Wick W, Neuro-oncology Working Group of the German Cancer S (2013) Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. Neuro-oncology 15:1017–1026. https://doi.org/10.1093/neuonc/not043
DeWitt JC, Jordan JT, Frosch MP, Samore WR, Iafrate AJ, Louis DN, Lennerz JK (2017) Cost-effectiveness of IDH testing in diffuse gliomas according to the 2016 WHO classification of tumors of the central nervous system recommendations. Neuro-oncology 19:1640–1650. https://doi.org/10.1093/neuonc/nox120
Ludmir EB, Mandel JJ, McAleer MF, de Groot JF (2019) Disparities along the glioblastoma clinical trials landscape. Neuro-oncology 21:285–286. https://doi.org/10.1093/neuonc/noy176
Vanderbeek AM, Rahman R, Fell G, Ventz S, Chen T, Redd R, Parmigiani G, Cloughesy TF, Wen PY, Trippa L, Alexander BM (2018) The clinical trials landscape for glioblastoma: is it adequate to develop new treatments? Neuro-oncology 20:1034–1043. https://doi.org/10.1093/neuonc/noy027
Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466. https://doi.org/10.1016/s1470-2045(09)70025-7
Funding
No funding was obtained for this project.
Author information
Authors and Affiliations
Contributions
MY (data curation, formal analysis, writing—original draft, writing—review and editing), EBL (data curation, formal analysis, writing - original draft,writing—review and editing), JJM (conceptualization, data curation, formal analysis, investigation, methodology, writing—original draft, and writing—review and editing), JT (data curation, writing—review and editing, AJP (data curation, writing—review and editing), AJ (data curation, writing—review and editing), MFM (conceptualization, data curation, formal analysis, investigation, methodology, writing—original draft, and writing—review and editing), JFG (conceptualization, data curation, formal analysis, investigation, methodology, writing—original draft, and writing—review and editing).
Corresponding author
Ethics declarations
Conflict of interest
Dr. John de Groot—Grant or Research Support: Sanofi-Aventis, Astrazeneca, EMD-Serono; Eli Lilly, Novartis, Deciphera Pharmaceuticals, Mundipharma; Paid Consultant: Celldex; Deciphera Pharmaceuticals, AbbVie, FivePrime Therapeutics, Inc., GW Pharma, Carthera, Eli Lilly, Boston Biomedical Inc.,Taiho Pharmaceuticals, Kairos Venture Investments, Syneos Health, Monteris, Agios, Mundipharma, Blue Earth Diagnostics; Advisory Boards: Genentech, Celldex, Foundation Medicine, Inc., Novogen, Deciphera, Astrazeneca, Insys Therapeutics, Kadmon, Merck, Eli Lilly, Novella Clinical, Blue Earth Diagnostics; Other Relevant Financial or Material Interests: DSMB: VBL Therapeutics; DSMB: Novella; VBI Vaccines, Inc.; Stock Ownership: Ziopharm Oncology, Gilead; Company Employment (Spouse): Ziopharm Oncology. None of the other authors have any conflict of interests to report.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors and was a retrospective study performed with approval of the IRB of the respective institutions.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Youssef, M., Ludmir, E.B., Mandel, J.J. et al. Treatment strategies for glioblastoma in older patients: age is just a number. J Neurooncol 145, 357–364 (2019). https://doi.org/10.1007/s11060-019-03304-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-019-03304-x